Skip to main content

Advertisement

SpringerLink
Log in

Strategies to Increase HMG-CoA Reductase Inhibitor Use After Acute Myocardial Infarction

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Coronary artery disease with its accompanying complication of acute myocardial infarction (MI) is one of the major causes of death in the modern world. A variety of both primary and secondary prevention strategies have been developed for the treatment of acute MI. One of the more important of these strategies is the prescription of HMG-CoA reductase inhibitors. HMG-CoA reductase inhibitors have the potential to positively affect the outcome of acute MI in a variety of ways including the reduction of low-density lipoprotein-cholesterol levels and stabilisation of the atherosclerotic plaque. Multiple large randomised clinical trials have documented the potential of HMG-CoA reductase inhibitors to reduce both shortand long-term mortality after acute MI. This benefit exists regardless of age, gender, clinical presentation, or even baseline lipid levels. However, despite this overwhelming amount of evidence supporting the use of HMG-CoA reductase inhibitors in the post-MI setting, multiple studies have documented the presence of a significant ‘treatment gap’. Indeed, often, less than half of acute MI patients who would benefit from HMG-CoA reductase inhibitor therapy actually receive it. The reasons for the low utilisation of HMG-CoA reductase inhibitors in the acute MI patient are many, but may include poor communication, the high cost of treatment, the lack of associated symptoms and confusion regarding appropriate lipid levels to target. One approach that has been tried to address these issues is the development of institutional programmes specifically targeted to increase the use of HMG-CoA reductase inhibitors in acute MI patients. These programmes, often managed by nurses or pharmacists, have been piloted in several institutions. They have been effectively implemented in both inpatient and outpatient settings. In most cases they have been implemented without a great increase in expense. They have often increased the use of HMG-CoA reductase inhibitors to >90%. Most importantly, they have documented a significant improvement in the long-term survival of acute MI patients. Based on these preliminary studies, it is recommended that the implementation of these strategies be considered by most healthcare institutions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Fig. 1
Table I
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. National Heart, Lung, and Blood Institute. Fact book: fiscal year 1995. Bethesda (MD): US Dept of Health and Human Services, 1996 Mar: 30–52

    Google Scholar 

  2. Farmer JA, Gotto Jr AM. Dyslipidemia and other risk factors for coronary artery disease. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. 5th ed. Philadelphia (PA): WB Saunders, 1997: 1126–60

    Google Scholar 

  3. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham study. Ann Intern Med 1979; 90(1): 85–91

    PubMed  CAS  Google Scholar 

  4. Libby P. Inflammation in atherosclerosis. Nature 2002; 420(6917): 868–74

    Article  PubMed  CAS  Google Scholar 

  5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340(2): 15–26

    Google Scholar 

  6. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91(11): 2844–50

    Article  PubMed  CAS  Google Scholar 

  7. Bybee KA, Wright RS, Kopecky SL. Effect of early statin therapy after acute coronary syndromes: a concise review of the recent data. Cardiol Rev 2002; 10(5): 301–5

    Article  PubMed  Google Scholar 

  8. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643–50

    Article  PubMed  CAS  Google Scholar 

  9. Kinlay S, Selwyn AP, Delagrange D, et al. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol 1996; 7: 389–97

    Article  PubMed  CAS  Google Scholar 

  10. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712–9

    Article  PubMed  CAS  Google Scholar 

  11. Koenig W, Hehr R, Ditschuneit HH, et al. Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein(a)? J Clin Pharmacol 1992; 32: 539–45

    Article  PubMed  CAS  Google Scholar 

  12. Beigel Y, Fuchs J, Snir M, et al. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol 1991; 31: 512–7

    PubMed  CAS  Google Scholar 

  13. Lacoste L, Lam JY, Hung J, et al. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172–7

    Article  PubMed  CAS  Google Scholar 

  14. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100(3): 230–5

    Article  PubMed  CAS  Google Scholar 

  15. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64–70

    Article  PubMed  CAS  Google Scholar 

  16. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol 1999; 10: 435–41

    Article  PubMed  CAS  Google Scholar 

  17. Spagnoli LG, Bonanno E, Mauriello A, et al. Multicentric inflammation in epicardial coronary arteries of patients dying of acute myocardial infarction. J Am Coll Cardiol 2002; 40(9): 1579–88

    Article  PubMed  Google Scholar 

  18. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9

    Google Scholar 

  19. White HD, Simes RJ, Anderson NE, et al. Impact of pravastatin therapy on the risk of stroke: results from the LIPID study. N Engl J Med 2000; 343: 317–26

    Article  PubMed  CAS  Google Scholar 

  20. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001–9

    Article  PubMed  CAS  Google Scholar 

  21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study: randomized placebo-controlled trial of cholesterol lowering with simvastatin in 20,536 high-risk individuals. Lancet 2002; 360: 7–22

    Article  Google Scholar 

  22. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPSATexCAPS. JAMA 1998; 279(20): 1615–22

    Article  PubMed  CAS  Google Scholar 

  23. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. ASCOT investigators. Lancet 2003; 361(9364): 1149–58

    Article  PubMed  CAS  Google Scholar 

  24. Blazing MA, De Lemos JA, Dyke CK, et al. The A-to-Z trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001; 142(2): 211–7

    Article  PubMed  CAS  Google Scholar 

  25. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. Swedish Register of Cardiac Intensive Care (RIKS-HIA). JAMA 2001; 285: 430–6

    Article  PubMed  CAS  Google Scholar 

  26. Home BD, Muhlestein JB, Carlquist JF, et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000; 36(6): 1774–80

    Article  Google Scholar 

  27. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357(9262): 1063–8

    Article  PubMed  CAS  Google Scholar 

  28. Hamm CW, Heeschen C, Boehm M, et al. Role of statins in patients with acute coronary syndromes. Circulation 2000; 102Suppl. 2: 11–435

    Google Scholar 

  29. Bybee KA, Wright RS, Williams B, et al. Effect of concomitant or very early statin administration on in-hospital mortality and re-infarction rates in patients with acute myocardial infarction. Am J Cardiol 2001; 87: 771–4

    Article  PubMed  CAS  Google Scholar 

  30. Bybee KA, Wright RS, Williams B. Differential benefit from early treatment with a statin agent after non-ST elevation myocardial infarction compared with ST elevation myocardial infarction. Circulation 2000; 102Suppl. 2: 11–614

    Google Scholar 

  31. Schiele R, Gitt AK, Heer T, et al. Early statin use in acute myocardial infarction is associated with a reduced hospital mortality: results of the Mitra-2. Circulation 2000; 102Suppl. 2: 11–435

    Google Scholar 

  32. Walter DH, Fichtischerer S, Britten MB, et al. Initiation of statin therapy immediately after stent implantation: profound benefit in patients with acute coronary syndromes [abstract]. Circulation 2000; 102Suppl. 2: 11–435

    Google Scholar 

  33. Giugliano RP, Antman EM, Thompson SL, et al. Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower postdischarge 1-year mortality [abstract]. J Am Coll Cardiol 2001; 37Suppl. A: 316A

    Google Scholar 

  34. Cannon CP, McCabe CH, Bentley J, et al. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI 16 [abstract]. J Am Coll Cardiol 2001; 37(A): 334A

    Google Scholar 

  35. Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. SYMPHONY and 2nd SYMPHONY Investigators. JAMA 2002; 287: 3087–95

    Article  PubMed  CAS  Google Scholar 

  36. Kayikcioglu M, Turkoglu C, Kultursay H, et al. The short-term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction [abstract]. Circulation 1999; 100Suppl. 1: 1–303

    Google Scholar 

  37. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes: The MIRACL study: a randomised controlled trial. JAMA 2001; 285: 1711–8

    Article  PubMed  CAS  Google Scholar 

  38. Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (+/−cholestyramine/niacin) initiated immediately after a coronary event (the randomised Lipid-Coronary Artery Disease [L-CAD] study). Am J Cardiol 2000; 86: 1293–8

    Article  PubMed  CAS  Google Scholar 

  39. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Circulation 2002; 105: 1446–52

    Article  PubMed  CAS  Google Scholar 

  40. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100(9): 1016–30

    Article  PubMed  CAS  Google Scholar 

  41. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995; 273: 1509–14

    Article  PubMed  CAS  Google Scholar 

  42. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83: 1303–7

    Article  PubMed  CAS  Google Scholar 

  43. Frolkis JP, Zyzanski SJ, Schwartz JM, et al. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 1998; 98: 851–5

    Article  PubMed  CAS  Google Scholar 

  44. Miller M, Byington R, Hunninghake D, et al. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Arch Intern Med 2000; 160: 343–7

    Article  PubMed  CAS  Google Scholar 

  45. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. National Registry of Myocardial Infarction 3 Participants. Circulation 2001; 103: 38–44

    Article  PubMed  CAS  Google Scholar 

  46. Muhlestein JB, Home BD, Bair TL, et al. Usefulness of inhospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001; 87(3): 257–61

    Article  PubMed  CAS  Google Scholar 

  47. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. Circulation 2001; 103(23): 2768–70

    Article  PubMed  CAS  Google Scholar 

  48. Jackson G. The role of statins in acute coronary syndromes: managing the unmet need. Int J Clin Pract 2000; 54(7): 445–9

    PubMed  CAS  Google Scholar 

  49. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001; 87(7): 819–22

    Article  PubMed  CAS  Google Scholar 

  50. Pearson RR, Home BD, Allen Maycock CA, et al. An institutional discharge medication program reduces future cardiovascular readmissions and mortality: an analysis of 43,841 patients with coronary artery disease [abstract]. J Am Coll Cardiol 2002; 39Suppl. A: 452A

    Article  Google Scholar 

  51. Denton TA, Fonarow GC, LaBresh KA, et al. Secondary prevention after coronary bypass: the American Heart Association “Get with the Guidelines” program. Ann Thorac Surg 2003; 75(3): 758–60

    Article  PubMed  Google Scholar 

  52. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the NCEP expert panel (Adult Treatment Panel II). JAMA 1993; 269: 3015–23

    Google Scholar 

  53. Lappe DL, Kralick-Goldberg S, French TK, et al. Implementing approved guidelines in heart disease: can hospital discharge medication rates be improved? [abstract]. J Card Fail 2000; 6Suppl. B: 76

    Google Scholar 

  54. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. ASCOT investigators. Lancet 2003; 361(9364): 1149–58

    Article  PubMed  CAS  Google Scholar 

  55. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. Lescol Intervention Prevention Study (LIPS) Investigators. JAMA 2002; 287(24): 3215–22

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No funding was provided to assist in the preparation of this manuscript. Potential conflicts of interest include: (i) Speakers Bureau for Merck, Pfizer and Bristol-Myers Squibb; and (ii) research funds from Merck and Abbott.

Author information

Authors and Affiliations

  1. Cardiovascular Department, Division of Cardiology, LDS Hospital, Salt Lake City, Utah, USA

    Joseph B. Muhlestein

Authors
  1. Joseph B. Muhlestein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph B. Muhlestein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muhlestein, J.B. Strategies to Increase HMG-CoA Reductase Inhibitor Use After Acute Myocardial Infarction. Drugs Aging 21, 583–595 (2004). https://doi.org/10.2165/00002512-200421090-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200421090-00003

Keywords

Search

Navigation